Crohn's Disease - Pipeline Review, H1 2013 -






 

Published: February 2013 | Pages: 256

Global Markets Direct’s, 'Crohn's Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Crohn's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Crohn's Disease. Crohn's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope


- A snapshot of the global therapeutic scenario for Crohn's Disease.
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Crohn's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

 Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Crohn's Disease Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Crohn's Disease 11
Crohn's Disease Therapeutics under Development by Companies 13
Crohn's Disease Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Crohn's Disease Therapeutics – Products under Development by Companies 24
Crohn's Disease Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Crohn's Disease Therapeutics Development 30
Bristol-Myers Squibb Company 30
Johnson & Johnson 31
Osiris Therapeutics, Inc. 32
Sequella, Inc. 33
Amgen Inc. 34
Sanofi-Aventis 35
AstraZeneca PLC 36
GlaxoSmithKline plc 37
AbGenomics International, Inc. 38
Novo Nordisk A/S 39
Cytokine PharmaSciences, Inc. 40
Takeda Pharmaceutical Company Limited 41
Celltrion, Inc. 42
Sylentis 43
Axcan Pharma Inc. 44
Pfizer Inc. 45
Teva Pharmaceutical Industries Limited 46
Zeria Pharmaceutical Co Ltd 47
Celgene Corporation 48
4SC AG 49
iCo Therapeutics Inc. 50
Enzo Biochem, Inc. 51
NPS Pharmaceuticals, Inc. 52
Soligenix, Inc. 53
ProMetic Life Sciences Inc. 54
Pluristem Therapeutics Inc. 55
Alba Therapeutics Corporation 56
Viron Therapeutics, Inc. 57
Farmacija d.o.o. Tuzla 58
Neovacs SA 59
Altor BioScience Corporation 60
Alder Biopharmaceuticals Inc. 61
Allozyne, Inc. 62
Coronado Biosciences, Inc. 63
NovImmune SA 64
Txcell SA 65
Selexys Pharmaceuticals Corporation 66
TcL Pharma SAS 67
Xencor, Inc. 68
Giuliani S.p.A. 69
Sirnaomics, Inc. 70
Winston Pharmaceuticals, Inc. 71
S.L.A. Pharma AG 72
Stelic Institute & Co. 73
Centocor Ortho Biotech, Inc. 74
Amunix, Inc. 75
Immune Technologies and Medicine 76
Advancell 77
Crohn's Disease – Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
laquinimod sodium - Drug Profile 84
tofacitinib - Drug Profile 86
eldelumab - Drug Profile 90
PDA-001 - Drug Profile 91
tetomilast - Drug Profile 93
remestemcel-L - Drug Profile 94
PF-04236921 - Drug Profile 96
teduglutide - Drug Profile 98
TNF-Kinoid - Drug Profile 100
NI-0401 - Drug Profile 102
vedolizumab - Drug Profile 103
mercaptopurine - Drug Profile 105
ustekinumab - Drug Profile 106
clazakizumab - Drug Profile 108
vercirnon sodium - Drug Profile 110
vidofludimus - Drug Profile 112
SGX-203 - Drug Profile 116
SelK2-Anti-PSGL-1 - Drug Profile 117
OvaSave - Drug Profile 118
MP-196 - Drug Profile 119
ALT-836 - Drug Profile 120
larazotide acetate - Drug Profile 122
STNM-01 - Drug Profile 124
infliximab - Drug Profile 125
GED-0301 - Drug Profile 126
SQ-641 - Drug Profile 127
VT-346 - Drug Profile 128
Xpro-1595 - Drug Profile 129
budesonide - Drug Profile 130
bertilimumab - Drug Profile 131
mesalamine - Drug Profile 133
zucapsaicin Capsule - Drug Profile 134
Alequel - Drug Profile 135
semapimod - Drug Profile 136
PBI-1737 - Drug Profile 137
TSO - Drug Profile 138
metronidazole - Drug Profile 140
AMG-139 - Drug Profile 142
PF-00547659 - Drug Profile 143
AMG-181 - Drug Profile 144
mesalamine - Drug Profile 145
Drug For Crohn's Disease And Ulcerative Colitis - Drug Profile 147
adalibumab + [azathioprine] + [prednisone] - Drug Profile 148
Autologous Haematopoietic Stem Cell Transplantation - Drug Profile 150
AZ-17 - Drug Profile 151
PLX–IBD - Drug Profile 152
dexamethasone acetate - Drug Profile 153
infliximab biosimilar - Drug Profile 155
infliximab biosimilar - Drug Profile 157
adalimumab biosimilar - Drug Profile 159
AJM-300 - Drug Profile 160
TRK-170 - Drug Profile 162
STP-432 - Drug Profile 163
NN-8828 - Drug Profile 164
Leukothera - Drug Profile 166
CrohnsVax - Drug Profile 167
Cytokine-Like Proteins - Drug Profile 168
Allogenic Adipose-Derived Stem Cells - Drug Profile 169
infliximab biosimilar - Drug Profile 170
MMP Blocker - Drug Profile 171
D-9421-C - Drug Profile 172
ONS-3010 - Drug Profile 173
ONS-3015 - Drug Profile 174
adalimumab biosimiar - Drug Profile 175
AMX-256 - Drug Profile 176
ANs-42 - Drug Profile 177
ABK-16 - Drug Profile 178
Autologous Bone Marrow Derived Mesenchymal Stromal (MSC) Cells - Drug Profile 179
QBECO SSI - Drug Profile 180
SAR-252067 - Drug Profile 182
Atrosab - Drug Profile 183
Drug For Inflammatory Bowel Diseases - Drug Profile 184
BA-024 - Drug Profile 185
metenkefalin + tridecactide - Drug Profile 186
PH-46A - Drug Profile 187
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 188
Tumor Necrosis Factor Receptor 25 Agonists - Drug Profile 189
Lactococcus lactis For Crohn's Disease - Drug Profile 190
ITP-01 - Drug Profile 191
Crohn's Disease Therapeutics – Drug Profile Updates 192
Crohn's Disease Therapeutics – Discontinued Products 232
Crohn's Disease Therapeutics - Dormant Products 234
Crohn's Disease – Product Development Milestones 241
Featured News & Press Releases 241
Appendix 250
Methodology 250
Coverage 250
Secondary Research 250
Primary Research 250
Expert Panel Validation 250
Contact Us 251
Disclaimer 251



List of Tables

Number of Products Under Development for Crohn's Disease, H1 2013 16
Products under Development for Crohn's Disease – Comparative Analysis, H1 2013 17
Number of Products under Development by Companies, H1 2013 19
Number of Products under Development by Companies, H1 2013 (Contd..1) 20
Number of Products under Development by Companies, H1 2013 (Contd..2) 21
Number of Products under Development by Companies, H1 2013 (Contd..3) 22
Number of Products under Development by Companies, H1 2013 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H1 2013 24
Comparative Analysis by Late Stage Development, H1 2013 25
Comparative Analysis by Mid Clinical Stage Development, H1 2013 26
Comparative Analysis by Early Clinical Stage Development, H1 2013 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Development by Companies, H1 2013 (Contd..1) 30
Products under Development by Companies, H1 2013 (Contd..2) 31
Products under Development by Companies, H1 2013 (Contd..3) 32
Products under Development by Companies, H1 2013 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2013 34
Bristol-Myers Squibb Company, H1 2013 35
Johnson & Johnson, H1 2013 36
Osiris Therapeutics, Inc., H1 2013 37
Sequella, Inc., H1 2013 38
Amgen Inc., H1 2013 39
Sanofi-Aventis, H1 2013 40
AstraZeneca PLC, H1 2013 41
GlaxoSmithKline plc, H1 2013 42
AbGenomics International, Inc., H1 2013 43
Novo Nordisk A/S, H1 2013 44
Cytokine PharmaSciences, Inc., H1 2013 45
Takeda Pharmaceutical Company Limited, H1 2013 46
Celltrion, Inc., H1 2013 47
Sylentis, H1 2013 48
Axcan Pharma Inc., H1 2013 49
Pfizer Inc., H1 2013 50
Teva Pharmaceutical Industries Limited, H1 2013 51
Zeria Pharmaceutical Co Ltd, H1 2013 52
Celgene Corporation, H1 2013 53
4SC AG, H1 2013 54
iCo Therapeutics Inc., H1 2013 55
Enzo Biochem, Inc., H1 2013 56
NPS Pharmaceuticals, Inc., H1 2013 57
Soligenix, Inc., H1 2013 58
ProMetic Life Sciences Inc., H1 2013 59
Pluristem Therapeutics Inc., H1 2013 60
Alba Therapeutics Corporation, H1 2013 61
Viron Therapeutics, Inc., H1 2013 62
Farmacija d.o.o. Tuzla, H1 2013 63
Neovacs SA, H1 2013 64
Altor BioScience Corporation, H1 2013 65
Alder Biopharmaceuticals Inc., H1 2013 66
Allozyne, Inc., H1 2013 67
Coronado Biosciences, Inc., H1 2013 68
NovImmune SA, H1 2013 69
Txcell SA, H1 2013 70
Selexys Pharmaceuticals Corporation, H1 2013 71
TcL Pharma SAS, H1 2013 72
Xencor, Inc., H1 2013 73
Giuliani S.p.A., H1 2013 74
Sirnaomics, Inc., H1 2013 75
Winston Pharmaceuticals, Inc., H1 2013 76
S.L.A. Pharma AG, H1 2013 77
Stelic Institute & Co., H1 2013 78
Centocor Ortho Biotech, Inc., H1 2013 79
Amunix, Inc., H1 2013 80
Immune Technologies and Medicine, H1 2013 81
Advancell, H1 2013 82
Assessment by Monotherapy Products, H1 2013 83
Assessment by Combination Products, H1 2013 84
Assessment by Stage and Route of Administration, H1 2013 86
Assessment by Stage and Molecule Type, H1 2013 88
Crohn's Disease Therapeutics – Drug Profile Updates 197
Crohn's Disease Therapeutics – Discontinued Products 237
Crohn's Disease Therapeutics – Discontinued Products (Contd..1) 238
Crohn's Disease Therapeutics – Dormant Products 239
Crohn's Disease Therapeutics – Dormant Products (Contd..1) 240
Crohn's Disease Therapeutics – Dormant Products (Contd..2) 241
Crohn's Disease Therapeutics – Dormant Products (Contd..3) 242
Crohn's Disease Therapeutics – Dormant Products (Contd..4) 243
Crohn's Disease Therapeutics – Dormant Products (Contd..5) 244
Crohn's Disease Therapeutics – Dormant Products (Contd..6) 245



List of Figures

Number of Products under Development for Crohn's Disease, H1 2013 16
Products under Development for Crohn's Disease – Comparative Analysis, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 24
Late Stage Products, H1 2013 25
Mid Clinical Stage Products, H1 2013 26
Early Clinical Stage Products, H1 2013 27
Discovery and Pre-Clinical Stage Products, H1 2013 28
Assessment by Monotherapy Products, H1 2013 83
Assessment by Combination Products, H1 2013 84
Assessment by Route of Administration, H1 2013 85
Assessment by Stage and Route of Administration, H1 2013 86
Assessment by Molecule Type, H1 2013 87
Assessment by Stage and Molecule Type, H1 2013 88